| Literature DB >> 18261221 |
Bayram Edemir1, Sunil M Kurian, Martin Eisenacher, Detlef Lang, Carsten Müller-Tidow, Gert Gabriëls, Daniel R Salomon, Eberhard Schlatter.
Abstract
BACKGROUND: Microarray analysis provides a powerful approach to identify gene expression alterations following transplantation. In patients the heterogeneity of graft specimens, co-morbidity, co-medications and the challenges in sample collection and preparation complicate conclusions regarding the underlying mechanisms of graft injury, rejection and immune regulation.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18261221 PMCID: PMC2262896 DOI: 10.1186/1471-2164-9-71
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Correlation and clustering of the samples. A) Correlation analyses of the samples showed the expected results with higher correlation between control group (ctr) and syngeneic group (sTX) samples compared to acute rejection group (aTX). B) The representative scatter plots of all genes between different samples shows, that the observed correlation is not dominated by a small number of high-expressing genes.
Figure 2Differently expressed genes between the control, syngeneic and allogeneic group. Class comparisons were performed using BRB array tools to identify genes with significant changes in expression levels between the syngeneic group (sTX_con) or the allogeneic group (aTX_con) compared to the control group and between allogeneic and syngeneic group (aTX_sTX; Fig. 2A). Genes with a p-value < 0.001 were classified as significant regulated. The complete lists with the significant regulated genes are provided with this manuscript (see additional file 1). The Venn diagram in Fig. 2B shows the number of overlapping genes. The changes in expression compared to control for selected genes were analyzed by real time PCR using specific primer pairs or TaqMan gene expression assays. Relative changes were evaluated using the 2-ΔΔCt method. The changes in gene expression after allogeneic transplantation are shown in Fig. 2C and the results for the syngeneic transplantation group in Fig. 2D. The black columns show the corresponding expression levels on the arrays (ratio of mean signal intensities). MMP7. IL10, C4bpa, Tap1 and Tap2 were not differently expressed after syngeneic transplantation on the array. There was no corresponding probe set for FoxP3 on the array.
Selection of significant up-regulated expression of cytokines, cytokine receptors, chemokines, chemokine receptors, regulatory or protective genes after allogeneic transplantation compared to control group.
| 121.2 | 1387711_at | interleukin 10 | Il10 |
| 84.1 | 1370790_at | interferon gamma | Ifng |
| 41.6 | 1391384_at | tumor necrosis factor (TNF superfamily, member 2) | Tnf |
| 15.4 | 1398256_at | interleukin 1 beta | Il1b |
| 13.1 | 1368592_at | interleukin 1 alpha | Il1a |
| 8.6 | 1369665_a_at | interleukin 18 | Il18 |
| 8.4 | 1368763_at | interleukin 3 | Il3 |
| 7.4 | 1369191_at | interleukin 6 | Il6 |
| 6.1 | 1369208_at | interleukin 7 | Il7 |
| 17 | 1389092_at | interleukin 2 receptor, gamma | Il2rg |
| 13.6 | 1387591_at | interleukin 2 receptor, alpha chain | Il2ra |
| 11.8 | 1369697_at | interleukin 8 receptor, beta | Il8rb |
| 10.1 | 1387394_at | interleukin 2 receptor, beta chain | Il2rb |
| 3.5 | 1370728_at | interleukin 13 receptor, alpha 1 | Il13ra1 |
| 3 | 1386987_at | interleukin 6 receptor | Il6r |
| 139.7 | 1382454_at | chemokine (C-X-C motif) ligand 9 | Cxcl9 |
| 122.8 | 1387831_at | small inducible cytokine subfamily C, member 1 (lymphotactin) | Xcl1 |
| 39.3 | 1387969_at | chemokine (C-X-C motif) ligand 10 | Cxcl10 |
| 25.7 | 1391925_at | chemokine (C-C motif) ligand 19 (predicted) | Ccl19_predicted |
| 21.5 | 1369815_at | chemokine (C-C motif) ligand 3 | Ccl3 |
| 17.5 | 1367973_at | chemokine (C-C motif) ligand 2 | Ccl2 |
| 16.5 | 1379365_at | chemokine (C-X-C motif) ligand 11 | Cxcl11 |
| 15.2 | 1370832_at | small inducible cytokine A4 | Ccl4 |
| 6.7 | 1387316_at | chemokine (C-X-C motif) ligand 1 | Cxcl1 |
| 5.8 | 1369983_at | chemokine (C-C motif) ligand 5 | Ccl5 |
| 55.9 | 1369290_at | chemokine (C-C) receptor 5 | Ccr5 |
| 53.5 | 1370083_at | macrophage inflammatory protein-1 alpha receptor gene | Ccr1 |
| 45.9 | 1393929_at | chemokine (C-C motif) receptor 6 (predicted) | Ccr6_predicted |
| 41.1 | 1387742_at | chemokine (C-C motif) receptor 2 | Ccr2 |
| 11.2 | 1368192_at | chemokine (C-X-C motif) receptor 3 | Cxcr3 |
| 219.364 | 1369764_at | complement component 4 binding protein, alpha | C4bpa |
| 121.25 | 1387711_at | interleukin 10 | Il10 |
| 55.975 | 1368482_at | B-cell leukemia/lymphoma 2 related protein A1 | Bcl2a1 |
| 39.519 | 1371252_at | suppressor of cytokine signaling 1 | Socs1 |
| 39 | 1387835_at | interleukin 1 receptor antagonist | Il1rn |
| 36.72 | 1387608_at | indoleamine 2,3-dioxygenase | Indo |
| 28.885 | 1382622_at | cystatin F (leukocystatin) (predicted) | Cst7_predicted |
| 23.06 | 1370080_at | heme oxygenase (decycling) 1 | Hmox1 |
| 17.922 | 1370113_at | inhibitor of apoptosis protein 1 | Birc3 |
| 16.732 | 1368695_at | complement component 4 binding protein, beta | C4bpb |
| 8.305 | 1387638_a_at | cytotoxic T-lymphocyte-associated protein 4 | Ctla4 |
| 229.344 | 1385414_at | CD8 antigen, alpha chain | Cd8a |
| 144.253 | 1387378_at | ficolin B | Fcnb |
| 103.106 | 1370628_at | granzyme B | Gzmb |
| 67.326 | 1379293_at | granzyme A | Gzma |
| 35.114 | 1393917_at | CD163 antigen (predicted) | Cd163_predicted |
| 30.581 | 1387472_at | CD3 antigen delta polypeptide | Cd3d |
| 28.319 | 1387739_at | CD8 antigen, beta chain | Cd8b |
| 25 | 1370096_at | perforin 1 (pore forming protein) | Prf1 |
| 18.368 | 1370483_at | CD244 natural killer cell receptor 2B4 | Cd244 |
Overrepresented GO categories compared to control within the syngeneic transplantation group. The top 10 significantly overrepresented GO categories on the third level (p < 0.05, Fisher's exact test, with Benjamini and Hochberg correction) related to biological process (BP), cellular component (CC) and molecular function (MF) in the set of genes down- or up-regulated after syngeneic transplantation (sTX) compared to control are shown in Table 2 The numbers indicate the quantity of genes corresponding with the GO-terms.
| BP | organic acid metabolism | 57 | 1,1E-10 |
| BP | carboxylic acid metabolism | 56 | 1,5E-10 |
| BP | amino acid and derivative metabolism | 41 | 7,1E-9 |
| BP | amino acid metabolism | 31 | 2,2E-6 |
| BP | nitrogen compound metabolism | 40 | 8,3E-6 |
| BP | amine metabolism | 38 | 9,7E-6 |
| BP | sulfur amino acid metabolism | 10 | 1,8E-5 |
| BP | amino acid derivative metabolism | 18 | 6,0E-5 |
| BP | amino acid catabolism | 13 | 1,1E-4 |
| BP | nitrogen compound catabolism | 15 | 1,2E-4 |
| CC | mitochondrion | 59 | 1,9E-7 |
| CC | microbody | 14 | 4,0E-4 |
| CC | peroxisome | 14 | 4,0E-4 |
| MF | oxidoreductase activity | 59 | 3,2E-9 |
| MF | catalytic activity | 195 | 1,5E-6 |
| MF | lyase activity | 20 | 1,7E-3 |
| BP | mitotic cell cycle | 44 | 5,3E-7 |
| BP | cell division | 30 | 6,1E-7 |
| BP | cell cycle | 81 | 6,8E-7 |
| BP | cell adhesion | 70 | 2,5E-6 |
| BP | mitosis | 29 | 2,6E-6 |
| BP | M phase of mitotic cell cycle | 29 | 2,7E-6 |
| BP | cell proliferation | 83 | 1,1E-5 |
| BP | M phase | 33 | 3,9E-5 |
| BP | regulation of cell cycle | 54 | 7,9E-5 |
| BP | regulation of progression through cell cycle | 54 | 7,9E-5 |
| CC | extracellular matrix | 56 | 3,5E-16 |
| CC | extracellular matrix (sensu Metazoa) | 54 | 2,7E-15 |
| CC | intracellular non-membrane-bound organelle | 144 | 6,0E-13 |
| CC | non-membrane-bound organelle | 144 | 6,0E-13 |
| CC | collagen | 16 | 2,0E-7 |
| CC | ribosome | 36 | 2,4E-5 |
| CC | cytoskeleton | 76 | 4,1E-5 |
| CC | spindle | 17 | 4,1E-5 |
| CC | microtubule cytoskeleton | 40 | 4,2E-5 |
| CC | chromosome | 36 | 4,4E-5 |
| MF | structural molecule activity | 75 | 3,7E-8 |
| MF | extracellular matrix structural constituent | 23 | 9,6E-8 |
| MF | structural constituent of ribosome | 32 | 9,3E-5 |
| MF | collagen binding | 8 | 1,7E-2 |
| MF | pattern binding | 17 | 4,3E-2 |
| MF | enzyme inhibitor activity | 29 | 4,7E-2 |
Overrepresented GO categories compared to control within the allogeneic transplantation group. The top 10 significantly overrepresented GO categories on the third level (p < 0.05, Fisher's exact test, with Benjamini and Hochberg correction) related to biological process (BP), cellular component (CC) and molecular function (MF) in the set of genes down- or up-regulated after allogeneic transplantation (aTX) compared to control are shown in Table 3. The numbers indicate the quantity of genes corresponding with the GO-terms.
| BP | nitrogen compound metabolism | 119 | 8,1E-11 |
| BP | catabolism | 130 | 3,7E-6 |
| BP | cellular metabolism | 864 | 3,9E-4 |
| BP | transport | 408 | 5,1E-4 |
| BP | establishment of localization | 459 | 1,4E-3 |
| BP | excretion | 18 | 5,1E-3 |
| CC | organelle inner membrane | 110 | 1,7E-25 |
| CC | mitochondrial envelope | 116 | 1,1E-23 |
| CC | organelle envelope | 128 | 1,9E-15 |
| CC | cytoplasm | 695 | 5,8E-15 |
| CC | organelle membrane | 165 | 9,3E-15 |
| CC | mitochondrial lumen | 41 | 4,6E-7 |
| CC | membrane fraction | 171 | 8,8E-7 |
| MF | electron carrier activity | 45 | 7,6E-17 |
| MF | oxidoreductase activity, acting on NADH or NADPH | 37 | 1,8E-12 |
| MF | primary active transporter activity | 55 | 2,5E-8 |
| MF | metal ion transporter activity | 39 | 4,3E-7 |
| MF | oxidoreductase activity, acting on the CH-CH group of donors | 22 | 8,8E-6 |
| MF | oxidoreductase activity, acting on CH-OH group of donors | 38 | 1,1E-4 |
| MF | coenzyme binding | 21 | 2,0E-4 |
| BP | immune response | 283 | 1,7E-44 |
| BP | defense response | 292 | 8,1E-43 |
| BP | response to pest, pathogen or parasite | 180 | 6,4E-26 |
| BP | response to other organism | 180 | 2,3E-24 |
| BP | macromolecule metabolism | 797 | 1,4E-23 |
| BP | cell activation | 78 | 2,7E-14 |
| BP | cell death | 198 | 1,9E-13 |
| BP | response to wounding | 141 | 1,8E-11 |
| BP | primary metabolism | 1079 | 8,0E-9 |
| BP | cell cycle | 171 | 2,2E-8 |
| CC | ribonucleoprotein complex | 138 | 1,7E-22 |
| CC | intracellular non-membrane-bound organelle | 318 | 3,9E-18 |
| CC | nucleus | 581 | 3,0E-12 |
| CC | ribosome | 81 | 1,2E-11 |
| CC | cytosolic small ribosomal subunit (sensu Eukaryota) | 23 | 2,2E-8 |
| CC | T cell receptor complex | 14 | 1,5E-6 |
| CC | nuclear envelope | 44 | 2,0E-5 |
| CC | intracellular organelle | 1000 | 2,3E-5 |
| CC | spliceosome complex | 25 | 9,6E-5 |
| CC | proteasome complex (sensu Eukaryota) | 25 | 1,5E-4 |
| MF | RNA binding | 178 | 3,5E-31 |
| MF | cytokine binding | 30 | 8,5E-4 |
| MF | sugar binding | 36 | 6,8E-3 |
| MF | translation factor activity, nucleic acid binding | 33 | 8,6E-3 |
| MF | translation initiation factor activity | 22 | 1,3E-2 |
| MF | protease activator activity | 10 | 4,3E-2 |
Pathways with up- or down-regulated genes after syngeneic transplantation or allogeneic transplantation. Pathway charts were obtained using DAVID functional annotation tools (p < 0.05, Fisher's exact test, p-value with Benjamini correction). Pathways with a significantly elevated number of genes down- or up-regulated after syngeneic transplantation (sTX) or allogeneic transplantation (aTX) compared to control are shown Table 4. The numbers indicate the genes affected within the pathways.
| tryptophan metabolism | 13 | ribosome | 22 |
| methionine metabolism | 7 | cell cycle | 28 |
| valine, leucine and isoleucine degradation | 11 | ribosome | 13 |
| lysine degradation | 9 | focal adhesion | 31 |
| fatty acid metabolism | 11 | ecm-receptor interaction | 16 |
| pyruvate metabolism | 9 | cell communication | 16 |
| beta-alanine metabolism | 7 | ||
| propanoate metabolism | 8 | ||
| butanoate metabolism | 9 | ||
| selenoamino acid metabolism | 6 | ||
| caprolactam degradation | 5 | ||
| alkaloid biosynthesis II | 5 | ||
| limonene and pinene degradation | 5 | ||
| glycine, serine and threonine metabolism | 7 | ||
| oxidative phosphorylation | 48 | antigen processing and presentation | 46 |
| fatty acid metabolism | 29 | ribosome | 43 |
| valine, leucine and isoleucine degradation | 25 | cell cycle | 50 |
| glutathione metabolism | 21 | proteasome | 22 |
| citrate cycle (tca cycle) | 13 | t cell receptor signaling pathway | 45 |
| pyruvate metabolism | 17 | type I diabetes mellitus | 28 |
| butanoate metabolism | 20 | hematopoietic cell lineage | 33 |
| glycine, serine and threonine metabolism | 17 | cell adhesion molecules (cams) | 50 |
| metabolism of xenobiotics by cytochrome p450 | 23 | cytokine-cytokine receptor interaction | 48 |
| tryptophan metabolism | 21 | toll-like receptor signaling pathway | 26 |
| propanoate metabolism | 14 | ||
| reductive carboxylate cycle (CO2 fixation) | 6 | ||
Figure 3Antigen presentation pathway. Ingenuity Pathways Knowledge Base was used to display pathways containing multiple differently expressed genes. Significant up-regulation of genes compared to control was observed in the canonical antigen presentation pathway after allogeneic transplantation. Up-regulated genes are highlighted in red the down-regulated genes are highlighted in green. The legend in Fig 3 applies also to Figs. 4-7.
Figure 4TCR signaling pathway. Ingenuity Pathways Knowledge Base was used to display pathways containing multiple differently expressed genes. Significant up-regulation of genes in the canonical TCR signaling pathway was observed after allogeneic transplantation. Up-regulated genes are highlighted in red the down-regulated genes are highlighted in green.
Figure 5Apoptosis signaling. In the same way as described in figure 3 significant regulated genes after allogeneic transplantation was observed in the canonical apoptosis signaling Up-regulated genes are highlighted in red the down-regulated genes are highlighted in green.
Figure 6Interferon signaling. Significant up-regulation of genes was also observed in the canonical interferon signaling pathway. Up-regulated genes are highlighted in red.
Figure 7Complement cascade. Significant regulated genes after allogeneic transplantation were associated with the canonical complement cascade using the Ingenuity Pathways Knowledge Base to visualize genes differently expressed in the selected pathway. Up regulated genes are highlighted in red the down regulated genes are highlighted in green.
Potential novel transcriptional markers for acute rejection
| 113.071 | 1378047_at | Spi-C transcription factor (Spi-1/PU.1 related) (predicted) | Spic_predicted |
| 98.594 | 1392308_at | phospholipase A2, group IID (predicted) | Pla2g2d_predicted |
| 94.648 | 1392496_at | Trypsin V-A | LOC312273 |
| 75.765 | 1368128_at | phospholipase A2, group IIA (platelets, synovial fluid) | Pla2g2a |
| 46.437 | 1369766_at | prostaglandin E receptor 2, subtype EP2 | Ptger2 |
| 39.419 | 1392171_at | chitinase 3-like 1 | Chi3l1 |
| 30.24 | 1370869_at | branched chain aminotransferase 1, cytosolic | Bcat1 |
| 26.936 | 1368413_at | amiloride binding protein 1 | Abp1 |